BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17539695)

  • 1. Implementation of monitoring and management guidelines for second-generation antipsychotics.
    Sernyak MJ
    J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging the gap between mental and physical health: a multidisciplinary approach.
    Vreeland B
    J Clin Psychiatry; 2007; 68 Suppl 4():26-33. PubMed ID: 17539697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
    Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
    CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating general health care in private community psychiatry practice.
    Goff DC
    J Clin Psychiatry; 2007; 68 Suppl 4():49-54. PubMed ID: 17539701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care issues in patients with mental illness.
    Kiraly B; Gunning K; Leiser J
    Am Fam Physician; 2008 Aug; 78(3):355-62. PubMed ID: 18711951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schizophrenia and comorbid metabolic disorders.
    Henderson DC
    J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
    De Hert M; van Eyck D; De Nayer A
    Int Clin Psychopharmacol; 2006 Mar; 21 Suppl 2():S11-5. PubMed ID: 16601508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness.
    Vergara-Rodriguez P; Vibhakar S; Watts J
    Pharmacol Ther; 2009 Dec; 124(3):269-78. PubMed ID: 19647020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atypical antipsychotic induced weight gain and metabolic disorders].
    Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
    Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of antipsychotics: recent controversies and future management.
    Fleischhacker WW
    J Clin Psychiatry; 2009 Mar; 70(3):e06. PubMed ID: 19317956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
    Tirupati S; Chua LE
    Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
    Van Gaal LF
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical health and schizophrenia.
    Mitchell AJ; Malone D
    Curr Opin Psychiatry; 2006 Jul; 19(4):432-7. PubMed ID: 16721177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.